Integrity Alliance’s Zevra Therapeutics ZVRA Stock Holding History

Integrity Alliance’s Portfolio ZVRA Stock Details ZVRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$10.3M	Buy	+938,167	New	+$11.1M	0.31%	78

Other funds holding ZVRA

Swedbank Stockholm, Sweden $118B AUM 40.52% 1-Year Est. Return

Retirement Planning Company of New England Warwick, Rhode Island $263M AUM 26.23% 1-Year Est. Return

Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return

MAM

Mystic Asset Management Warwick, Rhode Island $451M AUM 22.13% 1-Year Est. Return

Inspire Investing Meridian, Idaho $2.37B AUM 29.82% 1-Year Est. Return

Profund Advisors Bethesda, Maryland $3.48B AUM 66.96% 1-Year Est. Return

IFG Advisors St. Louis, Missouri $730M AUM 19.37% 1-Year Est. Return

Sterling Capital Management Charlotte, North Carolina $4.92B AUM 24.73% 1-Year Est. Return

Quaker Wealth Management Moorestown, New Jersey $341M AUM 9.06% 1-Year Est. Return

Bailard Foster City, California $4.94B AUM 25.15% 1-Year Est. Return

Integrity Alliance's ZVRA Position: Q3 2026 in Review

Integrity Alliance opened a new position in Zevra Therapeutics (ZVRA) in Q3 2026: 938,167 shares worth $10.3M. The stake represents 0.31% of the portfolio and ranks #78 among its holdings.

33 funds tracked by Wall St. Rank hold ZVRA as of Q3 2026.

Integrity Alliance held 938,167 shares of Zevra Therapeutics worth $10.3M as of Q3 2026.
Zevra Therapeutics was a new Integrity Alliance position in Q3 2026.
Zevra Therapeutics made up 0.31% of Integrity Alliance's portfolio in Q3 2026, its #78 holding.
33 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q3 2026.

Based on Integrity Alliance's 13F filing for Q3 2026, filed 29 Oct 2026.